LHC Group

LHC Group ROE

Delisted·Mar 3, 2023

The Return on Equity (ROE) of LHC Group (LHCG) as of Oct 24, 2026 is 2.50 %. In the previous year, Return on Equity (ROE) was 7.39 % — a change of -66.18% (lower).

ROE

2.50 %

YoY

-66.18%

Last updated:

In 2022, LHC Group's return on equity (ROE) was 2.50 %, a -66.18% increase from the 7.39 % ROE in the previous year.

The LHC Group ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2015
9.12 USD
Jan 1, 2016
9.26 USD
Jan 1, 2017
11.16 USD
Jan 1, 2018
4.83 USD
Jan 1, 2019
6.77 USD
Jan 1, 2020
7.30 USD
Jan 1, 2021
7.39 USD
Jan 1, 2022
2.50 USD
The LHC Group ROE history
YEARROEYoY
2.50 %-66.18%
7.39 %+1.22%
7.30 %+7.77%
6.77 %+40.30%
4.83 %-56.76%
11.16 %+20.58%
9.26 %+1.53%
9.12 %+33.06%
6.85 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

LHC Group Stock analysis

What does LHC Group do? The LHC Group Inc. is an American company operating in the healthcare sector. The company is based in Lafayette, Louisiana and was founded in 1994 by Keith Myers and Mark Baiada. Since then, the company has become one of the largest and most profitable providers of home care and hospital services in the USA. LHC Group's business model is based on providing high-quality services and building strong relationships with customers. The company offers a wide range of services, including home care, rehabilitation, infusion therapy, palliative care, hospice care, oncology care, and medical logistics. The various divisions of LHC Group are tailored to different individuals and needs. The home care division provides support to patients who are limited by illness or injury in their everyday tasks such as eating, getting dressed, and bathing. The company's rehabilitation division gives patients access to experienced therapists who help improve their mobility and well-being. The infusion and oncology division provides patients with specialized treatments such as chemotherapy and antibiotic infusions. LHC Group's palliative and hospice division offers palliative care and pain management to patients suffering from serious illnesses. The company's medical logistics division provides hospitals and other healthcare facilities with the necessary medical supplies and support. LHC Group works closely with hospitals and other healthcare facilities to ensure that patients receive the care and support they need after being discharged. The company takes pride in building and maintaining close relationships with customers and other providers. Over the years, LHC Group has made several successful acquisitions and operates both in the USA and internationally. The company has expanded its presence in the European market by acquiring a majority stake in the Serbian company Gastromed. In 2020, the company also formed a strategic partnership with the University of Southern California (USC) to enhance the provision of home healthcare and palliative care in the Los Angeles region. Overall, LHC Group is a leading company in the healthcare industry, providing high-quality services and products. The company has expanded its business in diverse ways and strives to continue offering innovative solutions to meet the needs of patients and customers. LHC Group is one of the most popular companies on Eulerpool.

ROE Details

Decoding LHC Group's Return on Equity (ROE)

LHC Group's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing LHC Group's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

LHC Group's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in LHC Group’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about LHC Group stock

Return on Equity (ROE) of LHC Group is 2.50 % in 2022.

Return on Equity (ROE) of LHC Group changed from 7.39 % to 2.50 %, representing a -66.18% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) LHC Group since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s LHC Group with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — LHC Group

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — LHC Group